Publications

2017

Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017. doi: 10.18632/oncotarget.19019. PubMed PMID: 28708596.

2016

Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH. Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016;13(4):365-71. doi: 10.1016/j.jacr.2015.11.002. PubMed PMID: 26774886.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. PubMed PMID: 26546453.

Pikman Y, Alexe G, Roti G, Saur Conway A, Furman A, Lee ES, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-15-2869. PubMed PMID: 28151717.

Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22(7):723-6. doi: 10.1038/nm.4120. PubMed PMID: 27270588; PMCID: PMC4938731.

Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Saur A, Tivey T, Zapf S, Bararia D, Zimber-Strobl U, Rodig SJ, Weigert O, Weinstock DM. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016;128(21):2517-26. doi: 10.1182/blood-2016-04-711176. PubMed PMID: 27742706.

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato AC, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP, Brown M. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell. 2016;29(6):846-58. doi: 10.1016/j.ccell.2016.04.012. PubMed PMID: 27238081; PMCID: PMC5124371.

Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016;30(1):190-9. doi: 10.1038/leu.2015.194. PubMed PMID: 26202935; PMCID: PMC4994896.

Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2016. doi: 10.1038/leu.2016.145. PubMed PMID: 27211268.

2015

Wang Y, Tseng JC, Sun Y, Beck AH, Kung AL. Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. Cold Spring Harb Protoc. 2015;2015(2):135-44. doi: 10.1101/pdb.top069930. PubMed PMID: 25646505.

Wang Y, Kung AL. 18F-FDG-PET/CT imaging of drug-induced metabolic changes in genetically engineered mouse lung cancer models. Cold Spring Harb Protoc. 2015;2015(2):176-9. doi: 10.1101/pdb.prot078246. PubMed PMID: 25646497.

Udemba A, Smith G, Nguyen QD, Kaliszczak M, Carroll L, Fortt R, Fuchter MJ, Aboagye EO. Design, synthesis and initial characterisation of a radiolabelled [(18)F]pyrimidoindolone probe for detecting activated caspase-3/7. Org Biomol Chem. 2015;13(19):5418-23. doi: 10.1039/c5ob00058k. PubMed PMID: 25865735.

Tseng JC, Kung AL. Quantitative bioluminescence imaging of mouse tumor models. Cold Spring Harb Protoc. 2015;2015(1):pdb prot078261. doi: 10.1101/pdb.prot078261. PubMed PMID: 25561617.

Tseng JC, Kung AL. In vivo imaging of endogenous enzyme activities using luminescent 1,2-dioxetane compounds. J Biomed Sci. 2015;22:45. doi: 10.1186/s12929-015-0155-x. PubMed PMID: 26100615; PMCID: PMC4477311.

Sun Y, Kung AL. Preclinical magnetic resonance imaging in mouse cancer models. Cold Spring Harb Protoc. 2015;2015(1):pdb prot078253. doi: 10.1101/pdb.prot078253. PubMed PMID: 25561616.

Pelish HE, Liau BB, Nitulescu, II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider EV, Jestel A, Zou G, Si C, Ebmeier CC, Bronson RT, Krivtsov AV, Myers AG, Kohl NE, Kung AL, Armstrong SA, Lemieux ME, Taatjes DJ, Shair MD. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015;526(7572):273-6. doi: 10.1038/nature14904. PubMed PMID: 26416749; PMCID: PMC4641525.

Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015;125(20):3133-43. doi: 10.1182/blood-2014-12-615906. PubMed PMID: 25833960; PMCID: PMC4432008.

McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ. [(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Transl Oncol. 2015;8(3):147-53. doi: 10.1016/j.tranon.2015.03.004. PubMed PMID: 26055171; PMCID: PMC4487789.

Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, Ramkissoon LA, Maire CL, Hubbell-Engler B, Knoff DS, Shacham S, Ligon KL, Kung AL. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol. 2015;17(5):697-707. doi: 10.1093/neuonc/nou303. PubMed PMID: 25366336; PMCID: PMC4482855.

Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M. Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015;29(7):1555-63. doi: 10.1038/leu.2015.46. PubMed PMID: 25703587; PMCID: PMC4497855.

Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, Livingston DM. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015;112(1):232-7. doi: 10.1073/pnas.1422165112. PubMed PMID: 25535366; PMCID: PMC4291641.

Bag S, Tseng JC, Rochford J. A BODIPY-luminol chemiluminescent resonance energy-transfer (CRET) cassette for imaging of cellular superoxide. Org Biomol Chem. 2015;13(6):1763-7. doi: 10.1039/c4ob02413c. PubMed PMID: 25500943.

2014

Tseng JC, Bailey D, Tupper T, Kung AL. Using Glow Stick Chemistry for Biological Imaging. Mol Imaging Biol. 2014. doi: 10.1007/s11307-014-0721-8. PubMed PMID: 24510470.

Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. PubMed PMID: 24569262; PMCID: 4023420.

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155-65. doi: 10.1038/leu.2013.115. PubMed PMID: 23588715; PMCID: PMC3883926.

O'Neill AF, Dearling JL, Wang Y, Tupper T, Sun Y, Aster JC, Calicchio ML, Perez-Atayde AR, Packard AB, Kung AL. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res. 2014;20(3):678-87. doi: 10.1158/1078-0432.CCR-13-1660. PubMed PMID: 24218512; PMCID: 3946397.

Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014;5(18):8737-49. doi: 10.18632/oncotarget.2372. PubMed PMID: 25228590; PMCID: PMC4226718.

Kim YI, Kim KW, Lee HK, Park J, Chung JW, Youn H, Kim SJ, Kim DH, Tseng JC, Lee JM. Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model. Anticancer Res. 2014;34(4):1715-22. PubMed PMID: 24692701.

Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, Kung AL, Wong KK. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 2014;20(5):1204-11. doi: 10.1158/1078-0432.CCR-13-1733. PubMed PMID: 24327273; PMCID: 3947539.

Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Jr., Bardeesy N, Wong KK. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014;28(5):479-90. doi: 10.1101/gad.231233.113. PubMed PMID: 24589777; PMCID: 3950345.

 

2013

Tseng JC, Kung AL. In vivo imaging method to distinguish acute and chronic inflammation. J Vis Exp. 2013(78). doi: 10.3791/50690. PubMed PMID: 23978851.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res. 2013;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. PubMed PMID: 24045185; PMCID: 3838895.

Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba, II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013;3(8):870-9. doi: 10.1158/2159-8290.CD-13-0015. PubMed PMID: 23715154; PMCID: 3753578.

Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013;73(8):2574-86. doi: 10.1158/0008-5472.CAN-12-1702. PubMed PMID: 23436801; PMCID: PMC3760004.

Kohnke T, Gomolka B, Bilal S, Zhou X, Sun Y, Rothe M, Baumgart DC, Weylandt KH. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int. 2013;2013:748160. doi: 10.1155/2013/748160. PubMed PMID: 24083240; PMCID: PMC3780524.

Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, Wang Q, Zhao J, Dorsch M, Buonamici S, Ligon KL, Kelleher JF, Segal RA. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013;19(11):1518-23. doi: 10.1038/nm.3328. PubMed PMID: 24076665; PMCID: PMC3923315.

Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161(1):117-27. doi: 10.1111/bjh.12231. PubMed PMID: 23373539; PMCID: 3980736.

Crompton BD, Carlton AL, Thorner AR, Christie AL, Du J, Calicchio ML, Rivera MN, Fleming MD, Kohl NE, Kung AL, Stegmaier K. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013;73(9):2873-83. doi: 10.1158/0008-5472.CAN-12-1944. PubMed PMID: 23536552.

Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777-90. doi: 10.1016/j.ccr.2013.11.003. PubMed PMID: 24332044; PMCID: 4018722.

 

2012

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Regnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209(2):259-73. doi: 10.1084/jem.20111694. PubMed PMID: 22271575; PMCID: 3280877.

Tseng JC, Wang Y, Banerjee P, Kung AL. Incongruity of imaging using fluorescent 2-DG conjugates compared to 18F-FDG in preclinical cancer models. Mol Imaging Biol. 2012;14(5):553-60. doi: 10.1007/s11307-012-0545-3. PubMed PMID: 22302178.

Tseng JC, Kung AL. In vivo imaging of inflammatory phagocytes. Chem Biol. 2012;19(9):1199-209. doi: 10.1016/j.chembiol.2012.08.007. PubMed PMID: 22999887.

Tseng JC, Benink HA, McDougall MG, Chico-Calero I, Kung AL. In Vivo Fluorescent Labeling of Tumor Cells with the HaloTag(R) Technology. Curr Chem Genomics. 2012;6:48-54. doi: 10.2174/1875397301206010048. PubMed PMID: 23115613; PMCID: 3480697.

Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. PubMed PMID: 22262760; PMCID: 3337713.

Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, Kung AL, Levine RL, Griffin JD, Sattler M. The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012;26(3):481-9. doi: 10.1038/leu.2011.225. PubMed PMID: 21860432; PMCID: PMC3227767.

Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012;3(7-8):503-11. doi: 10.1177/1947601912466555. PubMed PMID: 23264850; PMCID: 3527989.

McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, Mitsiades CS. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012;11(4):942-51. doi: 10.1158/1535-7163.MCT-11-0563. PubMed PMID: 22246439; PMCID: 3755358.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18(7):1118-22. doi: 10.1038/nm.2819. PubMed PMID: 22683780; PMCID: 3438345.

Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, Sicinski P. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22(4):438-51. doi: 10.1016/j.ccr.2012.09.015. PubMed PMID: 23079655; PMCID: 3487466.

Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Pena CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Janne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012;483(7391):613-7. doi: 10.1038/nature10937. PubMed PMID: 22425996; PMCID: 3385933.

 

2011

Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011;71(7):2686-96. doi: 10.1158/0008-5472.CAN-10-3513. PubMed PMID: 21447744; PMCID: 3070805.

Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208(9):1809-22. doi: 10.1084/jem.20110121. PubMed PMID: 21807868; PMCID: 3171095.

Mazzanti ML, Walvick RP, Zhou X, Sun Y, Shah N, Mansour J, Gereige J, Albert MS. Distribution of hyperpolarized xenon in the brain following sensory stimulation: preliminary MRI findings. PLoS One. 2011;6(7):e21607. doi: 10.1371/journal.pone.0021607. PubMed PMID: 21789173; PMCID: PMC3137603.

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, Xiao Y, Christie AL, Aster J, Settleman J, Gygi SP, Kung AL, Look T, Nakayama KI, DePinho RA, Wei W. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104-9. doi: 10.1038/nature09732. PubMed PMID: 21368833; PMCID: 3076007.

Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65. doi: 10.1016/j.ccr.2011.06.009. PubMed PMID: 21741596; PMCID: PMC4046888.

Cronican JJ, Beier KT, Davis TN, Tseng JC, Li W, Thompson DB, Shih AF, May EM, Cepko CL, Kung AL, Zhou Q, Liu DR. A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chem Biol. 2011;18(7):833-8. doi: 10.1016/j.chembiol.2011.07.003. PubMed PMID: 21802004; PMCID: PMC3154086.

2010

Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D, Straub C, Zawel L, Daley JF, Lazo-Kallanian S, Stone R, Galinsky I, Frank D, Kung AL, Griffin JD. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010;24(12):2100-9. doi: 10.1038/leu.2010.212. PubMed PMID: 20844561; PMCID: PMC4037865.

Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther. 2010;9(9):2468-77. doi: 10.1158/1535-7163.MCT-10-0232. PubMed PMID: 20807780; PMCID: 3967795.

Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17(3):298-310. doi: 10.1016/j.ccr.2009.12.047. PubMed PMID: 20227043; PMCID: 2897158.

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73. doi: 10.1038/nature09504. PubMed PMID: 20871596; PMCID: 3010259.

Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Adelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman C, Park SI, Kim HR, Padera R, Marto JA, Gray NS, Kung AL, Shapiro GI, Janne PA, Wong KK. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010;70(23):9827-36. doi: 10.1158/0008-5472.CAN-10-1671. PubMed PMID: 20952506; PMCID: 3043107.

2009

Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462(7270):182-8. doi: 10.1038/nature08543. PubMed PMID: 19907488; PMCID: 2951323.